Pharmacovigilance analysis of the US FDA Adverse Event Reporting System (FAERS) database provided a signal of association between subacute cutaneous lupus erythematosus and proton pump inhibitors.

Statistical analysis and published case reports confirmed the association.

Proton pump inhibitors should be discontinued if subacute cutaneous lupus erythematosus symptoms occur.